Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
CASI 
CASI Pharmaceuticals Inc (CASI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: CASI (3-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (-4.20%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 74.31% | Avg. Invested days 34 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.32M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.72 | 52 Weeks Range 1.09 - 7.50 | Updated Date 09/14/2025 |
52 Weeks Range 1.09 - 7.50 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.89 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date 2025-08-29 | When After Market | Estimate -0.47 | Actual -0.86 |
Profitability
Profit Margin -148.55% | Operating Margin (TTM) -256.53% |
Management Effectiveness
Return on Assets (TTM) -62.73% | Return on Equity (TTM) -1094.5% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 47295540 | Price to Sales(TTM) 1.12 |
Enterprise Value 47295540 | Price to Sales(TTM) 1.12 | ||
Enterprise Value to Revenue 1.5 | Enterprise Value to EBITDA 0.07 | Shares Outstanding 15492800 | Shares Floating 5977058 |
Shares Outstanding 15492800 | Shares Floating 5977058 | ||
Percent Insiders 48.38 | Percent Institutions 20.42 |
Upturn AI SWOT
CASI Pharmaceuticals Inc
Company Overview
History and Background
CASI Pharmaceuticals Inc. was founded in 1991. It focuses on developing and commercializing innovative therapeutics and pharmaceutical products, primarily in China and the United States. Over time, CASI has shifted its focus to acquiring, developing, and commercializing approved and late-stage pharmaceutical assets.
Core Business Areas
- Commercialization: Commercializing pharmaceutical products in China. This involves sales, marketing, and distribution activities.
- Drug Development: Developing novel therapeutics and biosimilars.
- Acquisition: Acquiring and in-licensing approved and late-stage pharmaceutical assets.
Leadership and Structure
Wei-Wu He, Ph.D., is the Chairman and Chief Executive Officer. The organizational structure includes departments for research and development, commercial operations, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- EVOMELA (Melphalan for Injection): An alkylating agent indicated as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation and for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate. Revenue information is not publicly available. Competitors include generic melphalan injections. No market share data.
- MARQIBO (vincristine sulfate liposome injection): Indicated for the treatment of adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) that is relapsed or refractory. Revenue information is not publicly available. Competitors include generic vincristine injections. No market share data.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high research and development costs, stringent regulatory requirements, and rapid technological advancements. The market is driven by an aging global population, increasing prevalence of chronic diseases, and growing demand for innovative therapies.
Positioning
CASI Pharmaceuticals is positioned as a specialty pharmaceutical company focused on acquiring and commercializing assets in oncology and hematology. Its competitive advantage lies in its focus on the China market and its ability to navigate the regulatory landscape.
Total Addressable Market (TAM)
The global oncology drugs market is projected to reach hundreds of billions of dollars. CASI is positioned to capture a share of this TAM through its commercialized and pipeline products, mainly focused on China.
Upturn SWOT Analysis
Strengths
- Focus on China market
- Experienced management team
- Established commercial infrastructure
- Portfolio of approved and late-stage products
- In-licensing capabilities
Weaknesses
- Limited product pipeline beyond current commercialized products
- Dependence on partners for product development and commercialization
- Relatively small market capitalization
- Financial losses
- Reliance on third-party manufacturing
Opportunities
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Acquisition of new assets
- Increase market share in China
- Regulatory approvals for pipeline products
Threats
- Competition from larger pharmaceutical companies
- Regulatory changes in China
- Patent expirations
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- JAZZ
- PACB
- MRTX
Competitive Landscape
CASI competes with larger pharmaceutical companies with greater resources and established market positions. CASI's advantages include its focus on the China market and its commercial infrastructure. CASI's disadvantages include limited product pipeline and dependence on partners.
Growth Trajectory and Initiatives
Historical Growth: Historically, CASI Pharmaceuticals has experienced fluctuating growth due to product development cycles and market dynamics.
Future Projections: Future growth is contingent on the successful commercialization of existing products and the development of new therapies. Analyst estimates are not available within this model.
Recent Initiatives: Recent initiatives include expanding the commercial team in China and advancing clinical trials for pipeline products. In-licensing new products is another key strategy.
Summary
CASI Pharmaceuticals is a specialty pharmaceutical company with a focus on the China market. While its established commercial infrastructure and portfolio of approved products are strengths, its limited product pipeline and dependence on partners present challenges. Successful execution of strategic initiatives and expansion into new therapeutic areas are crucial for future growth. It is important to monitor the competitive landscape and regulatory changes in China.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Third-party financial data providers
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. The information is not guaranteed to be accurate or complete. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CASI Pharmaceuticals Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1996-06-11 | CEO & Director Mr. David A. Cory M.B.A., R.Ph. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 233 | |
Full time employees 233 | |||
CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation and as a palliative treatment for patients with multiple myeloma. The company's hematology/oncology assets in pipeline include CNCT19, an autologous CD19 CAR-T investigative product; BI-1206, an novel anti-Fc"RIIB antibody for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. It has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.